# BV After Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT03540849** · PHASE2 · UNKNOWN · sponsor: **University Hospital, Caen** · enrollment: 58 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin (Bv)

## Key facts

- **NCT ID:** NCT03540849
- **Lead sponsor:** University Hospital, Caen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-07
- **Primary completion:** 2020-03-07
- **Final completion:** 2023-03-07
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2018-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03540849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03540849, "BV After Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03540849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*